Sign Out
Avoid concomitant use of Tolvaptan and moderate CYP3A inhibitors (eg, aprepitant, erythromycin, fluconazole, verapamil).
Concomitant use of Tolvaptan and strong CYP3A inhibitors (eg, ketoconazole, clarithromycin, ritonavir, saquinavir) is contraindicated.
Avoid concomitant use of Tolvaptan and strong CYP3A inducers (eg, rifampin, barbiturates, phenytoin, carbamazepine, St. John's Wort). If concurrent use is necessary, monitor patient response and increase Tolvaptan dose as necessary.
Dose reduction of Tolvaptan may be necessary when concurrent use with P-gp inhibitors (eg, cyclosporine, quinidine).
Continue with Google